Jazz Pharmaceuticals (NASDAQ:JAZZ) Hits New 1-Year Low at $111.11

Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Get Free Report) hit a new 52-week low during mid-day trading on Friday . The stock traded as low as $111.11 and last traded at $111.26, with a volume of 245497 shares trading hands. The stock had previously closed at $113.49.

Wall Street Analyst Weigh In

JAZZ has been the topic of several recent research reports. Piper Sandler raised their target price on shares of Jazz Pharmaceuticals from $171.00 to $188.00 and gave the company an "overweight" rating in a research note on Wednesday, March 20th. Needham & Company LLC reaffirmed a "buy" rating and issued a $220.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 20th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $195.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, February 29th. StockNews.com raised shares of Jazz Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Tuesday, January 30th. Finally, Stifel Nicolaus raised their target price on shares of Jazz Pharmaceuticals from $225.00 to $230.00 and gave the company a "buy" rating in a research note on Friday, March 15th. Two analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $195.08.

Jazz Pharmaceuticals Price Performance

The company has a market cap of $6.97 billion, a price-to-earnings ratio of 18.07, a PEG ratio of 1.58 and a beta of 0.59. The company's fifty day moving average price is $121.21 and its two-hundred day moving average price is $123.21. The company has a quick ratio of 1.85, a current ratio of 2.24 and a debt-to-equity ratio of 1.37.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.44 by ($0.04). The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1.01 billion. Jazz Pharmaceuticals had a return on equity of 31.27% and a net margin of 10.82%. On average, equities research analysts forecast that Jazz Pharmaceuticals plc will post 16.24 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO Philip L. Johnson acquired 12,000 shares of the firm's stock in a transaction that occurred on Friday, March 1st. The stock was acquired at an average cost of $119.65 per share, for a total transaction of $1,435,800.00. Following the completion of the acquisition, the chief financial officer now owns 27,932 shares in the company, valued at $3,342,063.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CFO Philip L. Johnson acquired 12,000 shares of the firm's stock in a transaction that occurred on Friday, March 1st. The stock was acquired at an average cost of $119.65 per share, for a total transaction of $1,435,800.00. Following the completion of the acquisition, the chief financial officer now owns 27,932 shares in the company, valued at $3,342,063.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Patricia Carr sold 1,936 shares of the stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $119.64, for a total value of $231,623.04. Following the transaction, the chief accounting officer now owns 8,364 shares of the company's stock, valued at $1,000,668.96. The disclosure for this sale can be found here. 4.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of JAZZ. Rise Advisors LLC grew its stake in Jazz Pharmaceuticals by 2,255.6% in the first quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company's stock valued at $26,000 after purchasing an additional 203 shares in the last quarter. Cape Investment Advisory Inc. grew its stake in Jazz Pharmaceuticals by 14,600.0% in the fourth quarter. Cape Investment Advisory Inc. now owns 294 shares of the specialty pharmaceutical company's stock valued at $36,000 after purchasing an additional 292 shares in the last quarter. ST Germain D J Co. Inc. bought a new position in Jazz Pharmaceuticals in the second quarter valued at approximately $40,000. Covestor Ltd grew its stake in Jazz Pharmaceuticals by 676.5% in the third quarter. Covestor Ltd now owns 396 shares of the specialty pharmaceutical company's stock valued at $51,000 after purchasing an additional 345 shares in the last quarter. Finally, Assetmark Inc. grew its stake in Jazz Pharmaceuticals by 37.1% in the fourth quarter. Assetmark Inc. now owns 440 shares of the specialty pharmaceutical company's stock valued at $54,000 after purchasing an additional 119 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.